GenSight Biologics has raised €22.5 million to prepare to bring gene therapy GS010 to market in the U.S. and Europe.

Aveo Pharmaceuticals’ multi-time failure tivozanib is on the cusp of winning approval in Europe, sending its stock on a tear.

BIO elected Alnylam CEO Maraganore as new chair, Neon tapped ex-Merrimack CFO Al-Wakeel, Biogen hired ex-Shire exec Gregory to lead human resources.

In our EuroBiotech roundup this week, Galapagos delays cystic fibrosis program, Zealand heads to phase 3 and Pluristem loses out on $30 million. 

In this week's EuroBiotech Report, J&J spins out Idorsia, Bavarian Nordic delays data, Woodford backs dementia fund and more. 

ElexoPharm has licensed inhibitors of the aldosterone synthase enzyme to Angion Biomedica.

Vineti is launching its cloud-based system to streamline company processes and accelerate patient access to cell and gene therapies.

Clinigen has signed exclusive agreements with Mitsubishi Tanabe, Shionogi and Romark to cooperate on expanded access to their medicines.

Sarepta Therapeutics has penned its second DMD gene therapy pact this year.

ImmunoCellular Therapeutics has suspended a phase 3 trial of its lead cancer vaccine after failing to raise the funds it needs to complete the study.